Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.38 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.35 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 8/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099003 | 0.85 | CCKBR (0.39) | CCKBRKMT2A | |
| SCHEMBL6096366 | 0.81 | CCKBR (0.52) | RIPK1CCKBRPKN1PKN2PARP1 | |
| SCHEMBL6096147 | 0.76 | RAB9A (0.38) | CCKBRKMT2A | |
| SCHEMBL6096557 | 0.75 | KMT2A (0.40) | CCKBRKMT2A | |
| SCHEMBL6097679 | 0.74 | CCKBR (0.40) | CCKBRKMT2A | |
| SCHEMBL6335210 | 0.73 | KMT2A (0.39) | CCKBRKMT2A | |
| SCHEMBL6096460 | 0.73 | CCKBR (0.56) | CCKBRPARP1DHODH | |
| SCHEMBL6097590 | 0.73 | KMT2A (0.40) | CCKBRKMT2A | |
| Lithium Ion SCHEMBL6335206 | 0.73 | KMT2A (0.39) | CCKBRKMT2A | |
| SCHEMBL6097387 | 0.72 | CNR2 (0.36) | CCKBRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034048-B2 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-04-25 | — | — | US | disclosed |
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-10-09 | — | — | US | disclosed |
| WO-2001085724-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS (III) | JAMES BLACK FOUNDATION LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191116-A1 | Gastrin and cholecystokinin receptor ligands (III) | CCKAR, CCKBR, GRPR | RIPK1 3153/4885CCKBR 2/4885PKN1 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.